Why Rigel Pharmaceuticals, Inc. Got Hammered Today

Image source: Getty Images.Rigel Pharmaceuticals (NASDAQ: RIGL) is down 23% at 11:30 a.m. EDT after the company reported a second phase 3 clinical trial testing for its spleen tyrosine kinase inhibitor, fostamatinib, in patients with adult chronic/persistent immune thrombocytopenia failed to live up to the results of the first trial.Continue reading

BING NEWS:
  • New York wins a share of $270M settlement against opioid manufacturer
    Attorney General Letitia James and attorneys general from five other states negotiated a preliminary settlement with Amneal Pharmaceuticals for fueling ... money New York will receive – have yet to be ...
    05/5/2024 - 6:33 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News